Docetaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed ovarian epithelial, fallopian tube, or peritoneal cavity cancer
• •* Stage IC-IV disease
• •* No borderline or low malignant potential tumors of any stage
• •Underwent initial surgical management, including staging, of early stage disease or surgical debulking of advanced stage disease\* NOTE: \*Patients may delay surgical debulking, if clinically indicated, until after study entry; these patients may receive several courses of neoadjuvant chemotherapy prior to surgical debulking, but before study entry
• •PATIENT CHARACTERISTICS:
• •Age
• •18 and over
• •Performance status
• •ECOG 0-2
• •Life expectancy
• •Not specified
• •Hematopoietic
• •Absolute neutrophil count ≥ 1,500/mm\^3
• •Hemoglobin ≥ 8.0 g/dL
• •Platelet count ≥ 100,000/mm\^3
• •Hepatic
• •Bilirubin normal
• •Meets 1 of the following criteria:
• •* Alkaline phosphatase (AP) normal AND AST or ALT ≤ 5 times upper limit of normal (ULN)
• •* AP ≤ 2.5 times ULN AND AST or ALT ≤ 1.5 times ULN
• •* AP ≤ 5 times ULN AND AST or ALT normal
• •Renal
• •Not specified
• •Other
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception during and for ≥ 3 months after completion of study treatment
• •No peripheral neuropathy \> grade 1
• •No prior malignancy with a poor prognosis that is at risk of relapse during study participation, as determined by the principal investigator
• •No history of severe hypersensitivity reaction to drugs formulated with polysorbate 80
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy
• •Not specified
• •Chemotherapy
• •No concurrent chemotherapy for another malignancy
• •Endocrine therapy
• •Not specified
• •Radiotherapy
• •Not specified
• •Surgery
• •See Disease Characteristics